AikaGraph is developed by We See You Wellness. AikaGraph Genealogy is our first public, working demonstration of the underlying method, live, in beta, with real users and real data, ahead of a wider commercial release.
We See You Wellness is Suzanne Freyjadis's women's wellness company, building Reina and its WellnessView feature. AikaGraph is the proprietary visualization technology, developed within We See You Wellness by Ulf Freyjadis, CTO & Co-Founder, that powers WellnessView, and whose underlying method extends beyond it. AikaGraph Genealogy is where that broader potential is demonstrated publicly.
AikaGraph was built by Ulf Freyjadis, drawing on roughly 27 years in healthcare IT, data integration, EHR/EMR systems, HL7, and clinical data pipelines, plus a Master's in Data Analytics (Oregon State University). That combination of domain depth and applied data-visualization work is what shaped AikaGraph's approach to messy, real-world relationship data.
We See You Wellness is relocating its founding team to Turku, with Business Finland's startup support process underway. Finland's patent and innovation ecosystem, and its startup infrastructure, made it the right base for the company, and for AikaGraph's continued development within it.
Finnish Patent and Registration Office (PRH), application no. 20265748, filed 2026-06-30. "Interactive data visualization and analysis tool for multistream time-series data."
AikaGraph Genealogy is the first public embodiment of a general-purpose method for exploring networked, time-based data. AikaGraph Health, a B2B application to clinical and EHR data, is in development. Other application areas have been explored internally; those conversations happen under NDA.
The genealogy beta is a real, working product with real testers and real GEDCOM data, not a pitch-deck rendering. It doubles as the clearest demonstration of the underlying method.
For deeper technical detail, a live walkthrough, or a Business Finland / due-diligence conversation, we're glad to talk under a short mutual NDA.